Preventing coronary artery disease begins with appropriate diagnosis in childhood.
Elevated low-density lipoprotein cholesterol (LDL-C) and elevated triglycerides (TGs) are risk factors for coronary artery disease.
- Evidence of atherosclerosis has been found in adolescents and young adults.
- Screening for dyslipidemia in children between 9 and 11 years of age can identify children with either primary (genetic) or secondary dyslipidemia (arising from lifestyle).
- Every dyslipidemia has both a genetic and lifestyle component, so this distinction is not perfectly defined but is useful for identifying the main etiology of the dyslipidemia.
Primary (Genetic) Dyslipidemia
Primary dyslipidemia tends to refer to elevated cholesterol that is the result of a genetic disorder.
The most common genetic dyslipidemia is familial hypercholesterolemia (FH).
- FH is autosomal dominant.
- Children homozygous for FH have very high LDL (generally >400 mg/dL).
- HDL-C and TG levels are usually normal or only mildly abnormal.
- Prevalence of homozygous FH is 1:160,000 to 400,000. (ref)(ref)
Data from the CASCADE FH Registry show that, among children homozygous for FH
- Xanthomas are often seen as early as 6 months of age.
- ~19% have aortic stenosis.
- ~44% have atherosclerotic cardiovascular disease (ASCVD).
- Median age of onset is 8.9 years.
Aggressive management of dyslipidemia in children homozygous for FH is needed to prevent ASCVD.
Approximately 1 in 250 people are heterozygous for FH.
- Children heterozygous for FH almost never have signs or symptoms.
- An LDL-C ≥160 mg/dL suggests heterozygous FH, particularly with a family history of significantly elevated cholesterol or preterm coronary artery disease.
- High-density lipoprotein cholesterol (HDL-C) and TG levels are usually normal, although some heterozygous for FH have lifestyle-induced dyslipidemia, presenting with low HDL-C and elevated TG in addition to LDL-C elevation.
- Individuals heterozygous for FH have substantially increased lifetime risk of accelerated atherosclerotic cardiovascular disease. 
Far less common is familial chylomicronemia syndrome (FCS, also called hyperlipoproteinemia type 1 or LPL deficiency).
- FCS affects about 1 in 1 million people worldwide.
- TG levels exceed 1,000 to 2,000 mg/dL.
- FCS generally manifests before 10 years of age, with about 25% presenting in the first year after birth.
- Children with FCS present with
- Abdominal pain attributable to acute pancreatitis
- Xanthomas, which are present in about 50% of cases
- Children with FCS present with
Secondary dyslipidemia
The most prevalent form of secondary dyslipidemia is atherogenic dyslipidemia.
- Commonly seen in individuals with obesity, insulin resistance, or type 2 diabetes.
- Patients have elevated serum triglycerides and low HDL-C.
- LDL-C levels may be within the reference range, but lipoprotein analysis shows increased concentrations of small, dense LDL particles. 
- The most effective treatment for this lipid disorder is change in diet and physical activity.
Other causes of secondary dyslipidemia
- Hypothyroidism, inflammatory or infectious conditions, renal disease, or diabetes.
- Rarely, liver disease, inborn errors of metabolism, and other conditions can cause dyslipidemia.
- Many medications can adversely affect lipid levels.
- Corticosteroids, isotretinoin, β-blockers, select chemotherapeutic or antiretroviral agents.
To reduce the risk of heart disease in children:
- The AAP endorses the recommendations of the National Heart, Lung, and Blood Institute (NHLBI).
- Dietary advice should be provided within the framework of shared decision-making and family-centered care.
- A clinician should assess willingness to change and identify potential barriers, including food costs and access.
- Advice should consider the age and development of the child, cultural norms, and personal preferences.

The development of this resource was made possible with support from Abbott. The AAP maintains full independence in its editorial and strategic activities. Financial supporters have no influence over AAP content, policies, or leadership decisions.
Last Updated
02/12/2026
Source
American Academy of Pediatrics